Jefferies analysts have published a note stating that Bayer is facing several challenges that require the company to consider strategic options. The halt of a late-stage clinical trial for experimental cardiovascular drug asundexian has increased financial risk, while falling share prices increase sensitivity to rising provisions and potential trial losses in a legal battle over its Roundup weedkiller. According to Jefferies, Bayer may need to sell assets and scrap dividends to buy time, but this may not be enough for large-scale investments needed in its pharma business. As a result, Jefferies has cut its recommendation on the stock from buy to hold. Despite this, shares are trading 0.3% higher following Monday’s heavy losses. (adria.calatayud@dowjones.com) Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8.
- Wed. Dec 6th, 2023
